Link here. RNS Number : 1434H Rex Bionics PLC · 95% Treatment Success and no adverse events · 95% of volunteers said they would like to use REX on a weekly basis · Next new RAPPER II sites will be the Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK; and Austin Health: Royal Talbot Rehabilitation Centre, Melbourne, Australia 27 November […]
Northridge, CA, USA and Cambridge, United Kingdom, 24 November 2015. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has entered into agreements with specialist wound-care distributors in France and the UK. In France, Medical Z® is a leader in […]
November 23, 2015. Link here. Overview of the symposium: 1, The Animal health industry and opportunities for innovation. 2. An overview of Nexvet: Details of the successful NV-01 pivotal study Next steps for Nexvet’s development programs. PETization and Nexvet’s R&D Finances and corporate structure Partnerships, market opportunities and near-term catalysts Q&A with Nexvet leadership 3. Companion […]
San Diego and Richmond, Va., USA, Ljubljana, Slovenia, and Sydney, Australia, November 19, 2015 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into a Clinical Trial Research Agreement with the University of Adelaide for the purpose of conducting a […]
Primary Endpoint Achieved Conference Call November 16th at 9:00AM ET DUBLIN, Ireland, Nov. 16, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced positive results from its pivotal safety and efficacy study of NV-01, the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain […]
Jeremy Curnock Cook on Sky News Business (The Perrett Report) Oct 27, 2015. Additionally it can be downloaded here: https://www.hightail.com/download/bXBZZUNxeFhRWUlsYzlVag
Australia, 20 October 2015 — ASX link here. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today the closing of a AUD$ 10,018,644 common stock placement to sophisticated and institutional investors through the issue of 107,727,358 shares at a price of AUD $0. […]
DUBLIN, Ireland, Oct. 19, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the initiation of a pilot field study for its product candidate NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) for the control of pain associated with osteoarthritis in cats. The initiation of this field study represents […]
Avita Medical announcement link here. · POSITIVE RESULTS FROM INTERIM UPDATE ON 20-PATIENT, RANDOMIZED, CONTROLLED STUDY OF RESTORATION OF PIGMENT IN HYPOPIGMENTED BURN SCARS · CONTINUED POSITIVE DATA FROM REPIGMENTATION TRIALS TO FORM BASIS FOR PIII PIVOTAL IDE SUBMISSION WITH US FDA NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom, 18 October 2013– Regenerative medicine Company Avita Medical Ltd. (ASX: AVH), (OTCQX:AVMXY) is […]
October 14, 2015: 9NEWS spoke exclusively to the first patient to undergo the new treatment that is giving hope to sufferers of back pain. Read more at http://www.9news.com.au/national/2015/10/14/19/04/aussie-innovation-gives-hope-to-back-pain-sufferers#b0dfx4DwJTTVgPDM.99